Literature DB >> 20086210

Ligand detection in the allosteric world.

Terry P Kenakin1.   

Abstract

Historically, traditional screening for ligands has been optimized to detect standard orthosteric agonists and antagonists. However, with increasing emphasis on cellular functional screens, more allosteric ligands are being discovered as potential drugs. In addition, there are theoretical reasons (increased selectivity, better control of physiological systems, separate control of affinity and efficacy) allosteric ligands may be preferred therapeutic chemical targets. These factors may make it desirable to design high-throughput screens to specifically detect functionally allosteric ligands. This article discusses the unique features of allosteric ligands as drugs as well as the special conditions that should be considered to optimize a high-throughput screen toward the detection of allosteric drugs. Finally, the likelihood of detecting allosteric ligands that have direct effects on cells (either conventional agonism or functionally selective effects) is discussed as well as the optimization of detection of such ligands in screening assays.

Mesh:

Substances:

Year:  2010        PMID: 20086210     DOI: 10.1177/1087057109357789

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  13 in total

Review 1.  Fine-tuning multiprotein complexes using small molecules.

Authors:  Andrea D Thompson; Amanda Dugan; Jason E Gestwicki; Anna K Mapp
Journal:  ACS Chem Biol       Date:  2012-07-23       Impact factor: 5.100

2.  The different ways through which specificity works in orthosteric and allosteric drugs.

Authors:  Ruth Nussinov; Chung-Jung Tsai
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 3.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 4.  Beyond traditional pharmacology: new tools and approaches.

Authors:  E V Gurevich; V V Gurevich
Journal:  Br J Pharmacol       Date:  2015-06-10       Impact factor: 8.739

Review 5.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

6.  Therapeutic potential of small molecules and engineered proteins.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

7.  Auto-inhibition at a ligand-gated ion channel: a cross-talk between orthosteric and allosteric sites.

Authors:  Xiang-Qun Hu
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

8.  Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and its stereoisomer as 5-HT2C receptor allosteric modulators.

Authors:  Chunyong Ding; Nicole M Bremer; Thressa D Smith; Patricia K Seitz; Noelle C Anastasio; Kathryn A Cunningham; Jia Zhou
Journal:  ACS Chem Neurosci       Date:  2012-04-19       Impact factor: 4.418

Review 9.  Direct and Propagated Effects of Small Molecules on Protein-Protein Interaction Networks.

Authors:  Laura C Cesa; Anna K Mapp; Jason E Gestwicki
Journal:  Front Bioeng Biotechnol       Date:  2015-08-24

Review 10.  Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.

Authors:  Hyeong-Min Lee; Yuna Kim
Journal:  Schizophr Res Treatment       Date:  2016-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.